Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is evaluate the efficacy and safety of tucidinostat in combination
with fulvestrant in patients with hormone-receptor positive advanced breast cancer.